Flavokawain A is a natural inhibitor of PRMT5 in bladder cancer

被引：0
|
作者：
Shuangjie Liu
Zhuonan Liu
Chiyuan Piao
Zhe Zhang
Chuize Kong
Lei Yin
Xi Liu
机构：
[1] The First Hospital of China Medical University,Department of Urology
来源：
Journal of Experimental & Clinical Cancer Research | / 41卷
关键词：
Protein arginine methyltransferase; Flavokawain A; Bladder cancer; Methylation disorder; Arginine methylation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models
    Chan-Penebre E.
    Kuplast K.G.
    Majer C.R.
    Boriack-Sjodin P.A.
    Wigle T.J.
    Johnston L.D.
    Rioux N.
    Munchhof M.J.
    Jin L.
    Jacques S.L.
    West K.A.
    Lingaraj T.
    Stickland K.
    Ribich S.A.
    Raimondi A.
    Scott M.P.
    Waters N.J.
    Pollock R.M.
    Smith J.J.
    Barbash O.
    Pappalardi M.
    Ho T.F.
    Nurse K.
    Oza K.P.
    Gallagher K.T.
    Kruger R.
    Moyer M.P.
    Copeland R.A.
    Chesworth R.
    Duncan K.W.
    Nature Chemical Biology, 2015, 11 (6) : 432 - 437
  • [22] The Where and the How of PRMT5
    Cheryl M. Koh
    Marco Bezzi
    Ernesto Guccione
    Current Molecular Biology Reports, 2015, 1 (1) : 19 - 28
  • [23] A novel MTA non-competitive PRMT5 inhibitor.
    Malik, Rohit
    Park, Peter K.
    Barbieri, Christopher M.
    Blat, Yuval
    Sheriff, Steven
    Weigelt, Carolyn A.
    Kopcho, Lisa M.
    Celiktas, Muge
    Ruzanov, Max
    Naglich, Joseph G.
    Price, Jennifer L.
    Harner, Mary
    Omalley, Kevin M.
    Deng, Jingjing
    Schmitz, William
    Li, Guo
    Ruan, Zheming
    Qin, Lan-ying
    Duke, Gerald J.
    Rodrigo, Iyoncy
    Witmer, Mark R.
    Harden, David G.
    Demes, Shilpa
    Arey, Brian J.
    Soars, Matt
    Fink, Brian E.
    Gavai, Ashvinikumar V.
    Vite, Gregory D.
    Voliva, Charles F.
    CANCER RESEARCH, 2021, 81 (13)
  • [24] Protein Arginine Methyltransferase 5 (PRMT5) Mutations in Cancer Cells
    Rasheed, Shayaan
    Bouley, Renee A.
    Yoder, Ryan J.
    Petreaca, Ruben C.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (07)
  • [25] Medicinal chemistry strategies targeting PRMT5 for cancer therapy
    Fu, Siyu
    Zheng, Qinwen
    Zhang, Dan
    Lin, Congcong
    Ouyang, Liang
    Zhang, Jifa
    Chen, Lei
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 244
  • [26] Protein Arginine Methyltransferase 5 (PRMT5) as an Anticancer Target and Its Inhibitor Discovery
    Wang, Yuanxiang
    Hu, Wenhao
    Yuan, Yanqiu
    JOURNAL OF MEDICINAL CHEMISTRY, 2018, 61 (21) : 9429 - 9441
  • [27] PRMT5: a putative oncogene and therapeutic target in prostate cancer
    Beketova, Elena
    Owens, Jake L.
    Asberry, Andrew M.
    Hu, Chang-Deng
    CANCER GENE THERAPY, 2022, 29 (3-4) : 264 - 276
  • [28] PRMT5: a putative oncogene and therapeutic target in prostate cancer
    Elena Beketova
    Jake L. Owens
    Andrew M. Asberry
    Chang-Deng Hu
    Cancer Gene Therapy, 2022, 29 : 264 - 276
  • [29] Tricyclic Carboxamide Derivatives as PRMT5 Inhibitors for Treating Cancer
    Sabnis, Ram W.
    ACS MEDICINAL CHEMISTRY LETTERS, 2022,
  • [30] PRMT5 restricts ERK activity
    Katharine H. Wrighton
    Nature Reviews Molecular Cell Biology, 2011, 12 : 689 - 689
12345